Hennion & Walsh Asset Management, Inc. Amylyx Pharmaceuticals, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.15 Billion
- Q1 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 83,236 shares of AMLX stock, worth $329,614. This represents 0.01% of its overall portfolio holdings.
Number of Shares
83,236
Previous 90,619
8.15%
Holding current value
$329,614
Previous $341,000
10.85%
% of portfolio
0.01%
Previous 0.02%
Shares
10 transactions
Others Institutions Holding AMLX
# of Institutions
141Shares Held
48.9MCall Options Held
281KPut Options Held
438K-
Perceptive Advisors LLC New York, NY6.77MShares$26.8 Million0.85% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA4.64MShares$18.4 Million2.86% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.69MShares$10.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$10.6 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC2.43MShares$9.61 Million0.0% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $232M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...